- Home
- RFM vs SKYE Comparison
RFM vs SKYE Comparison
Compare RFM & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFM
- SKYE
- Stock Information
- Founded
- RFM 2020
- SKYE 2012
- Country
- RFM United States
- SKYE United States
- Employees
- RFM N/A
- SKYE N/A
- Industry
- RFM Finance/Investors Services
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- RFM Finance
- SKYE Health Care
- Exchange
- RFM Nasdaq
- SKYE Nasdaq
- Market Cap
- RFM 92.3M
- SKYE 80.7M
- IPO Year
- RFM N/A
- SKYE N/A
- Fundamental
- Price
- RFM $14.78
- SKYE $1.59
- Analyst Decision
- RFM
- SKYE Buy
- Analyst Count
- RFM 0
- SKYE 7
- Target Price
- RFM N/A
- SKYE $18.00
- AVG Volume (30 Days)
- RFM 20.7K
- SKYE 192.9K
- Earning Date
- RFM 01-01-0001
- SKYE 03-20-2025
- Dividend Yield
- RFM 9.74%
- SKYE N/A
- EPS Growth
- RFM N/A
- SKYE N/A
- EPS
- RFM N/A
- SKYE N/A
- Revenue
- RFM N/A
- SKYE N/A
- Revenue This Year
- RFM N/A
- SKYE N/A
- Revenue Next Year
- RFM N/A
- SKYE N/A
- P/E Ratio
- RFM N/A
- SKYE N/A
- Revenue Growth
- RFM N/A
- SKYE N/A
- 52 Week Low
- RFM $12.89
- SKYE $1.56
- 52 Week High
- RFM $16.41
- SKYE $17.65
- Technical
- Relative Strength Index (RSI)
- RFM 29.96
- SKYE 30.46
- Support Level
- RFM $14.78
- SKYE $2.08
- Resistance Level
- RFM $15.28
- SKYE $2.44
- Average True Range (ATR)
- RFM 0.15
- SKYE 0.29
- MACD
- RFM -0.02
- SKYE -0.05
- Stochastic Oscillator
- RFM 7.41
- SKYE 2.27
About RFM RiverNorth Flexible Municipal Income Fund Inc.
RiverNorth Flexible Municipal Income Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is to seek current income exempt from regular U.S. federal income taxes. The fund's secondary investment objective is total return.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.